atorvastatin calcium


Summary: A pyrrole and heptanoic acid derivative,HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; AND TRIGLYCERIDES and to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS and prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.

Top Publications

  1. J B V, Ramakrishna S, Madhusudhan B. Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis. IET Nanobiotechnol. 2017;11:96-103 pubmed publisher
    ..25%) and showed a slow and sustained release of atorvastatin and curcumin 60.36 and 61.44%, respectively, in a span of 48?h. The drug-loaded nanocarriers found to be haemocompatible and qualified for drug delivery in atherosclerosis. ..
  2. Nixon D, Bosch R, Chan E, Funderburg N, Hodder S, Lake J, et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group S. J Clin Lipidol. 2017;11:61-69 pubmed publisher
  3. Guirao V, Martí Sistac O, DeGregorio Rocasolano N, Ponce J, Davalos A, Gasull T. Specific rescue by ortho-hydroxy atorvastatin of cortical GABAergic neurons from previous oxygen/glucose deprivation: role of pCREB. J Neurochem. 2017;143:359-374 pubmed publisher
    ..We propose that the statin metabolite o-ATV given post-OGD boosts the intrinsic pro-survival factor pCREB in large-GABAergic cortical neurons in vitro, this contributing to protect them from OGD...
  4. Carillion A, Feldman S, Na N, Biais M, Carpentier W, Birenbaum A, et al. Atorvastatin reduces ?-Adrenergic dysfunction in rats with diabetic cardiomyopathy. PLoS ONE. 2017;12:e0180103 pubmed publisher
    ..This effect is mediated by multiple modifications in expression of proteins in the ?-adrenergic signaling pathway, particularly through the NOS pathway. ..
  5. Peng P, Wei W, Long C, Li J. Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling. Biochem Biophys Res Commun. 2017;489:293-298 pubmed publisher
    ..Our study provides a fundamental evidence to repurpose atorvastatin for a potential treatment of glioblastoma. ..
  6. Bagdade J, Barter P, Quiroga C, Alaupovic P. Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial). Am J Cardiol. 2017;119:1753-1756 pubmed publisher
    ..In conclusion, these findings provide further evidence that the untoward effects of torcetrapib were attributable to off-target effects and not related to disturbances in lipoprotein transport. ..
  7. Millar J, Reyes Soffer G, Jumes P, Dunbar R, deGoma E, Baer A, et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest. 2015;125:2510-22 pubmed publisher NCT00990808. Merck & Co. Inc., Kenilworth, New Jersey, USA. Additional support for instrumentation was obtained from the National Center for Advancing Translational Sciences (UL1TR000003 and UL1TR000040). ..
  8. Fassett R, Robertson I, Ball M, Geraghty D, Coombes J. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clin Nephrol. 2014;81:75-85 pubmed publisher
    ..05). CKD patients with inflammation treated with atorvastatin had significantly less eGFR decline. Larger studies using statin therapy, specifically enrolling CKD patients with inflammation, may be worthwhile exploring. ..
  9. Maciejak A, Leszczynska A, Warchol I, Gora M, Kaminska J, Plochocka D, et al. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase. BMC Biotechnol. 2013;13:68 pubmed publisher

More Information


  1. Dennison T, Smith J, Badhan R, Mohammed A. Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Drug Des Devel Ther. 2017;11:811-826 pubmed publisher
  2. Melendez Q, Wooten C, Lopez D. Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells. Biochem Biophys Res Commun. 2017;492:103-108 pubmed publisher
    ..These results may explain why Prav works better for statin intolerant patients than other statins such as Atorv and Lov. ..
    ..This approach will provide lower RCPR within at least first 4-6 weeks after ACS and prevent RCPR increase during 12 months of DATT use in this patients group. ..
  4. Pasha R, Moon T. Coenzyme Q10 protects against statin-induced myotoxicity in zebrafish larvae (Danio rerio). Environ Toxicol Pharmacol. 2017;52:150-160 pubmed publisher
    ..Together, the implication of our results contributes to the understanding of the mechanisms of action of the statin-induced damage in this model fish species. ..
  5. Wiggers J, van Golen R, Verheij J, Dekker A, van Gulik T, Heger M. Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers. BMC Surg. 2017;17:35 pubmed publisher
    ..These patients require (pharmacological) interventions that specifically target the cholestasis-associated hepatopathology. ..
  6. Liang J, Yin K, Cao X, Han Z, Huang Q, Zhang L, et al. Attenuation of Low Ambient Temperature-Induced Myocardial Hypertrophy by Atorvastatin via Promoting Bcl-2 Expression. Cell Physiol Biochem. 2017;41:286-295 pubmed publisher
    ..Atv attenuated myocardial hypertrophy induced by cold exposure through inhibiting the downregulation of Bcl-2 in heart. It may provide a novel strategy for low temperature-induced myocardial hypertrophy treatment. ..
  7. Solberg R, Smith R, Almlöf M, Tewolde E, Nilsen H, Johansen H. Legumain expression, activity and secretion are increased during monocyte-to-macrophage differentiation and inhibited by atorvastatin. Biol Chem. 2015;396:71-80 pubmed publisher
    ..Interestingly, in our study, the active legumain produced by M2 macrophages was found to be inhibited by atorvastatin, which was reflected in aberrant cellular expression and processing. ..
  8. Jackevicius C, Chou M, Ross J, Shah N, Krumholz H. Generic atorvastatin and health care costs. N Engl J Med. 2012;366:201-4 pubmed publisher
  9. Nissen S. Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?. J Am Coll Cardiol. 2009;54:2363-5 pubmed publisher
  10. Mather J, Corradi J, Waszynski C, Noyes A, Duan Y, Grady J, et al. Statin and Its Association With Delirium in the Medical ICU. Crit Care Med. 2017;45:1515-1522 pubmed publisher
    ..Randomized trials of various statin types in hospitalized patients prone to delirium should validate their use in protection from delirium. ..
  11. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988-9 pubmed publisher
  12. Bedi P, Chalmers J, Graham C, Clarke A, Donaldson S, Doherty C, et al. A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study. Chest. 2017;152:368-378 pubmed publisher
    ..These effects may be due to an ability of atorvastatin to modulate neutrophil activation.; No.: NCT01299194; URL: ..
  13. Kamata T, Giblett S, Pritchard C. KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment. Blood. 2017;130:514-526 pubmed publisher
    ..In vivo treatment of the KRASG12D-induced LCH-like mouse with the cholesterol-lowering drug atorvastatin ameliorated the pathology, implicating statins as potential therapeutics against a subset of pulmonary LCH. ..
  14. Zhu B, Gong Y, Yan G, Wang D, Wang Q, Qiao Y, et al. Atorvastatin treatment modulates p16 promoter methylation to regulate p16 expression. FEBS J. 2017;284:1868-1881 pubmed publisher
    ..Taken together, we demonstrated that atorvastatin inhibits neointima formation through inducing p16 expression by affecting DNA methylation in the p16 promoter region. ..
  15. Yu H, Sun S, Gu X, Wang W, Gao X. Atorvastatin prolongs the lifespan of radiation?induced reactive oxygen species in PC-3 prostate cancer cells to enhance the cell killing effect. Oncol Rep. 2017;37:2049-2056 pubmed publisher
    ..In conclusion, ATO enhanced the cell killing effect of irradiation by reducing endogenous ROS levels and prolonging the lifespan of radiation?induced ROS via a decrease in the level of NOXs and SOD activity. ..
  16. Solomenchuk T, Semegen Bodak K, Slaba N, Chngrian G, Mysyshin M. [Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy]. Kardiologiia. 2014;54:40-3 pubmed
  17. Patel J, Snaith C, Thickett D, Linhartová L, Melody T, Hawkey P, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care. 2012;16:R231 pubmed publisher
    ..Acute administration of atorvastatin in patients with sepsis may prevent sepsis progression. Further multi-centre trials are required to verify these findings. International Standard Randomized Control Trial Registry ISRCTN64637517. ..
  18. Ma H, Liu Y, Xie H, Zhang G, Zhan H, Liu Z, et al. The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study. Medicine (Baltimore). 2017;96:e7351 pubmed publisher
    ..Collectively, our results indicate that simvastatin has comparable renoprotective effects to atorvastatin in ACS patients undergoing PCI. Further studies are warranted to confirm the comparative renoprotective effects of statins. ..
  19. Dolci G, Portela L, Onofre de Souza D, Medeiros Fossati A. Atorvastatin-induced osteoclast inhibition reduces orthodontic relapse. Am J Orthod Dentofacial Orthop. 2017;151:528-538 pubmed publisher
    ..This phenomenon sheds light on OPG as a molecular target that modulates maxillary bone metabolism and orthodontic relapse. ..
  20. Lee C, Zeldin D. Resolvin Infectious Inflammation by Targeting the Host Response. N Engl J Med. 2015;373:2183-5 pubmed publisher
  21. Madbouly Taha N, Salah A Yousof H, El Sayed S, Younis A, Ismail Negm M. Atorvastatin repurposing for the treatment of cryptosporidiosis in experimentally immunosuppressed mice. Exp Parasitol. 2017;181:57-69 pubmed publisher
    ..infection in the small intestine, colon, stomach and lungs of infected immunosuppressed mice in comparison to that induced by either Nitazoxanide or Atorvastatin alone. ..
  22. Bei W, Chen S, Li H, Wu D, Duan C, Chen P, et al. Comparing common doses (double-dose vs usual-dose) of atorvastatin for preventing contrast-induced acute kidney injury and mortality after coronary angiography. Medicine (Baltimore). 2017;96:e7501 pubmed publisher
    ..However, it increased the risk of CI-AKI in patients with a high contrast volume/CrCl. ..
  23. Zhang K, Zhai S, Zhang Z, Li K, Li T. Effect of Atorvastatin on lower extremity function of patients with hypertension and peripheral arterial disease. Pak J Pharm Sci. 2017;30:325-327 pubmed
    ..01). Short-term therapy with atorvastatin can significantly delay the decline of the walking speed in short distance and improve the lower-extremity function of patients with hypertension and PAD. ..
  24. Kilit C, Koçak F, Paşalı Kilit T. Comparison of the effects of high-dose atorvastatin and high-dose rosuvastatin on oxidative stress in patients with acute myocardial infarction: A pilot study. Turk Kardiyol Dern Ars. 2017;45:235-243 pubmed publisher
    ..Atorvastatin and rosuvastatin have similar effects on oxidative status in patients with AMI. Rosuvastatin affected HDL-C level more favorably than atorvastatin. ..
  25. Bowman L, Chen F, Sammons E, Hopewell J, Wallendszus K, Stevens W, et al. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitme. Am Heart J. 2017;187:182-190 pubmed publisher
    ..However, it is not known if these apparently favorable lipid changes translate into reductions in cardiovascular events...
  26. Walker M, Souza P, Colas R, Dalli J. 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis. FASEB J. 2017;31:3636-3648 pubmed publisher
    ..Walker, M. E., Souza, P. R., Colas, R. A., Dalli, J. 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis. ..
  27. Krishnan M, Kumar S, Ali S, Iyer R. Sudden bilateral anterior cerebral infarction: unusual stroke associated with unusual vascular anomalies. Postgrad Med J. 2013;89:120-1 pubmed publisher
  28. Safarova M, Trukhacheva E, Ezhov M, Afanas eva O, Afanas eva M, Tripoten M, et al. [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels]. Kardiologiia. 2011;51:9-16 pubmed
    ..This is the first study providing the evidence of using Lp(a) as one of therapeutic targets in patients with high Lp(a) levels for achieving beneficial effect on a surrogate marker of atherosclerosis. ..
  29. Quintana A, Hernandez J, Gonzalez C. Functional analysis of the zebrafish ortholog of HMGCS1 reveals independent functions for cholesterol and isoprenoids in craniofacial development. PLoS ONE. 2017;12:e0180856 pubmed publisher
    ..Moreover, our results describe a novel function for isoprenoids in facial development and collectively suggest that cholesterol regulates craniofacial development through versatile mechanisms. ..
  30. Qiu S, Zhuo W, Sun C, Su Z, Yan A, Shen L. Effects of atorvastatin on chronic subdural hematoma: A systematic review. Medicine (Baltimore). 2017;96:e7290 pubmed publisher
    ..Further high-quality studies focused on dosage, duration, hematoma size are needed to further elucidate the role of atorvastatin in the management of CSDH. ..
  31. Rosenson R, Farkouh M, Mefford M, Bittner V, Brown T, Taylor B, et al. Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. J Am Coll Cardiol. 2017;69:2696-2706 pubmed publisher
    ..The use of high-intensity statins following hospitalization for MI increased progressively from 2011 through 2014. ..
  32. Jackevicius C, Tu J, Krumholz H. Statins: is it safe and effective to use generic "equivalents"?. Can J Cardiol. 2013;29:408-10 pubmed publisher
  33. Daka A, Dimovski A, Kapedanovska A, Vavlukis M, Eftimov A, Labachevski N, et al. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers. Pharmazie. 2015;70:480-8 pubmed
    ..521T > C and c.571T > C SNPs may affect the inter-individual response to atorvastatin. Additional studies, with a large sample size, are needed to confirm this finding. ..
  34. Bellomo R. Perioperative Statins in Cardiac Surgery and Acute Kidney Injury. JAMA. 2016;315:873-4 pubmed publisher
  35. Mobarrez F, Egberg N, Antovic J, Bröijersén A, Jörneskog G, Wallen H. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb Res. 2012;129:95-7 pubmed publisher
  36. Lin L, Huang C, Chen J, Wu T, Leu H, Huang P, et al. Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study. Cardiovasc Diabetol. 2014;13:111 pubmed publisher
    ..This trial is registered at, NCT01386853. ..
  37. Zolcinski M, Ciesla Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost. 2012;107:1180-2 pubmed publisher
  38. Pasco J, Jacka F, Williams L, Henry M, Nicholson G, Kotowicz M, et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom. 2010;79:323-5 pubmed publisher
  39. Vaucher J, Marques Vidal P, Preisig M, Waeber G, Vollenweider P. Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease. Eur Heart J. 2014;35:958-9 pubmed publisher
  40. Li J, Liu J, Liang Z, He F, Yang L, Li P, et al. Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. Cell Death Dis. 2017;8:e2673 pubmed publisher
    ..The present work demonstrates that 'old' lipid-lowering drugs statins are novel weapons against RB-deficient tumors due to their effects on suppressing MCM7 protein levels. ..
  41. Yu Y, Zhu C, Liu C, Gao Y. Effect of Prior Atorvastatin Treatment on the Frequency of Hospital Acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke: A Multicenter Prospective Study. Biomed Res Int. 2017;2017:5642704 pubmed publisher
    ..This clinical study has been registered with ChiCTR-ROC-17010633 in Chinese Clinical Trial Registry. ..
  42. Kim J, Lee E, Lee E, Lee Y, Yoo H, Choi J, et al. Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis Res Ther. 2012;14:R187 pubmed publisher
    ..These results suggest that atorvastatin inhibits osteoclastogenesis and bone destruction in RA patients. ..
  43. Powers J, Murphy G, Ralph N, O Gorman S, Murphy J. Polypharmacy and sun exposure: Implications for mitochondrial DNA deletions in skin. J Photochem Photobiol B. 2017;173:397-403 pubmed publisher
  44. Madonna R, Renna F, Lanuti P, Perfetti M, Marchisio M, Briguori C, et al. The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. PLoS ONE. 2017;12:e0172800 pubmed publisher
    ..19(7), ii. 5(4), iii. 25(13), iv. 15(24)]. In this study, we found no evidence of acute changes in levels or activity of EPCs and CECs after high-dose lipid-lowering therapy in stable CAD patients. ..
  45. Akershoek J, Brouwer K, Vlig M, Boekema B, Beelen R, Middelkoop E, et al. Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds. PLoS ONE. 2017;12:e0179350 pubmed publisher
    ..Atorvastatin seems to accelerate the healing process in full thickness wounds possibly by dampening the pro-inflammatory response. ..
  46. Squizzato A, Romualdi E, Dentali F, Ageno W. Statins for acute ischemic stroke. Cochrane Database Syst Rev. 2011;:CD007551 pubmed publisher
    ..Insufficient data were available from randomized trials to establish if statins are safe and effective in cases of acute ischemic stroke and TIA. ..
  47. Zhang X, Chen X, Zhao W, Zeng C, Luo X, Li W, et al. GlcNAc Conjugated Atorvastatin with Enhanced Water Solubility and Cellular Internalization. Bioconjug Chem. 2017;28:2109-2113 pubmed publisher
    ..Moreover, both G-AT and G-K-AT were able to release atorvastatin and consequently achieve significant inhibition against 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase...
  48. Sathyapalan T, Kilpatrick E, Coady A, Atkin S. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2010;72:566-8 pubmed publisher
  49. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: a meta-analysis and meta-regression of randomized controlled trials. Int J Cardiol. 2012;158:285-9 pubmed publisher
  50. Blumenthal R, Ndumele C, Martin S. ASK NOT what CRP can do for you. J Am Coll Cardiol. 2013;62:730-1 pubmed publisher